AZ and GSK face Iraqi claims for UN oil-for-food program

6 July 2008

Officials in the Iraqi capital of Baghdad have begun criminal proceedings against a number of foreign companies, including UK drug major GlaxoSmithKline and Anglo-Swedish giant AstraZeneca, seeking about $10.0 billion in compensation over the scandal-ridden United Natons oil-for-food program. Both pharmaceutical firms, which are headquartered in London, have denied wrongdoing.

While he was in power, the oil-for-food program allowed Saddam Hussein to buy humanitarian supplies under the UN's supervision. However, an inquiry led by former US Federal Reserve chairman Paul Volcker revealed that corruption was rampant within the scheme, as foreign companies gave money to Iraqi officials to secure lucrative contracts or to buy oil for less than its true market value. A US criminal investigation into the program has led to several convictions and saw US oil giant Chevron pay $30.0 million to resolve liabilities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight